S227928

Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination With Venetoclax in Patients With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)

More Information

Trial Status
Not yet accepting
Trial Phase
Phase 1/2
Enrollment
132 patients (estimated)
Sponsors
Servier Bio-Innovation LLC
Tags
Antibody Drug Conjugate (ADC), Myeloid Cell Leukemia-1 (MCL-1) Inhibitor, CD74
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2114
NCT Identifier
NCT06563804

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.